BLUE RIBBON PANEL RECOMMENDATIONS
1. Network for direct patient engagement
Encourages patients to have their tumor
genome sequenced, automatically shares
the results through a network of linked databases,
and enables clinical trial enrollment when appropriate.
2. Cancer immunotherapy clinical trials network
A network of clinical trials in adult
and pediatric patients to evaluate
immunotherapies and vaccines.
3. Therapeutic target identification
to overcome drug resistance
Methods to identify mechanisms
of drug resistance and develop
therapeutic strategies to
prevent and overcome it.
4. A national cancer data ecosystem
for sharing and analysis
Develops the computational and bioinformatic
infrastructure necessary to share any kind of data with
anyone while maintaining privacy and security.
5. Fusion oncoproteins in pediatric cancer
Develop new therapeutics targeting
pediatric fusion proteins through
the use of new research models.
6. Symptom management research
Use patient reported outcomes to
develop evidence-based guidelines
to manage patient symptoms
throughout the course of clinical care.
7. Prevention and early detection:
implementation of evidence-based approaches
Use research to discover, test, and implement
strategies to reduce cancer risk, with
an initial focus on fully executing
established risk-reduction strategies.
8. Retrospective analysis of biospecimens
from patients treated with standard of care
Analyze existing and future samples from patients
receiving standard of care to enable the precise
use of standard treatments and
catalyze additional research.
9. Generation of human tumor atlases
Develop comprehensive maps of all
of the alterations within as many
different tumors as possible to fully
enable precision medicine.
10. Development of new
enabling cancer technologies
The new technologies will be
used to enable further discoveries
and improve patient care.
AACR hosts briefing with
June 1 June 6 June 28 June 29 September 7
Blue Ribbon Panel
Moonshot Summit held
at Howard University
Vice President Biden addresses
the ASCO Annual Meeting 2016
Blue Ribbon Panel
released FDA launches